BIOGNOSYS
26.5.2022 14:02:11 CEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass Spectrometry (ASMS) Annual Conference from June 5 to June 9 in Minneapolis (Minnesota, USA) where the company will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services.
Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration. In addition, their team of scientific experts will be present at booth #306 to answer questions and demo software.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly for proteomics data analysis and drug and biomarker discovery.
“Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys . "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.”
Spectronaut 16 provides the deepest proteome coverage available
At this year’s ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars. The first seminar, “Spectronaut 16: Reaching New Depths in DIA Proteomics with AI”, takes place on June 6 with presentations from Oliver Bernhardt (Biognosys) and guest speaker Birgit Schilling (The Buck Institute). The second seminar, “Spectronaut: The Best Ally for Your Visionary Projects,” on June 8 features guest speakers Jesper V. Olsen (University of Copenhagen) and Yansheng Liu (Yale University School of Medicine).
Further, Biognosys will present three posters, demonstrating the significant improvements in Spectronaut 16 for direct searches on complex DIA data with reduced analysis time, deep-learning-based scoring in a dia-PASEF analysis pipeline, and score identifications with minimal computation time through the neural network DeepXIC that uses ion chromatograms to score for identifications.
Biofluid biomarker discovery in neurodegenerative and chronic autoimmune diseases with TrueDiscovery
Biofluids can often be collected less invasively and more frequently than tissue samples to provide an overview of what is happening in the organism. At ASMS, Biognosys will highlight the clinical utility of its proprietary proteomics platform TrueDiscovery™ for unbiased biomarker discovery in biofluids in two oral presentations on June 6. The first oral presentation explores proteomics data collected from CSF and plasma samples in a clinical study in collaboration with Johns Hopkins University, aimed at detecting actionable biomarkers for Alzheimer’s disease (AD). The study identified several proteomic biomarkers for healthy and pathological individuals, some of which were shared in both sample types. The second talk will show data from a clinical study in collaboration with Takeda on Systemic Lupus Erythematosus (SLE). Novel as well as previously reported biomarkers have been identified in plasma and could be used to stratify the disease state. Moreover, disease-specific biomarkers could be described to differentiate patients with renal involvement.
Drug target identification in oncology with TrueTarget
In a collaboration between Biognosys, AstraZeneca, and Pelago Bioscience, proteomics was used to identify and characterize the protein targets of a kinase inhibitor compound across the CDK family. At ASMS, Biognosys will present data demonstrating the performance of its proprietary TrueTarget platform to reveal the target and binding affinity of the drug and highlight complementarities with two other proteomics-based techniques. The presentation builds further on earlier data from this study, published in ACS Chemical Biology.
Visit biognosys.com/asms2022 for a complete overview of Biognosys’ presence at ASMS.
About Spectronaut®
Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.
The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com .
About TrueDiscovery™
The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced patented Data Independent Acquisition (DIA)-based protein quantification technology co-invented by tech pioneers at Biognosys.
TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio .
About TrueTarget™
The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.
TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.
The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio .
About Biognosys
At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HappyRobot Raises $150 Million Series C to Build Enterprise Superintelligence4.8.2026 14:30:00 CEST | Press release
New funding led by Prysm Capital and co-led by Eurazeo will accelerate global growth as HappyRobot expands its engineering, deployment and go-to-market teams HappyRobot, the company putting AI agents to work across complex enterprise operations, today announced it has raised $150 million in Series C funding led by Prysm Capital and co-led by Eurazeo. Existing investors a16z, Base10, Y Combinator are doubling down with participation from strategics like Koch Disruptive Technologies (KDT), Orange, and T.Capital (Deutsche Telekom), Bankinter, Endeavor Catalyst, Kfund and Wave-X. The round values the company at $1.2 billion post-money, bringing total funding to around $200 million and marking a new stage of growth as enterprises deploy AI agents across mission-critical work. HappyRobot works with more than 150+ enterprise customers, including DHL, Kuehne + Nagel, Naturgy, Repsol, and Uber, and has grown 5x since raising its Series B late last year. After first proving its platform in logis
New 3D Flash Memory Technology from Kioxia and Sandisk Achieves Industry’s Highest Bit Density for QLC NAND4.8.2026 14:30:00 CEST | Press release
10th-generation QLC 3D flash memory represents a major leap forward for AI storage architectures, cloud platforms, and data‑intensive innovations Future of Memory and Storage Conference (FMS) – Kioxia Corporation, a subsidiary of Kioxia Holdings Corporation (TOKYO: 285A) and Sandisk Corporation (Nasdaq: SNDK) today unveiled their next-generation Quad-Level-Cell (QLC) 3D flash memory technology, which delivers up to 60% increase in bit density compared to their 8th-generation, surpassing 37 Gb/mm² and setting the industry benchmark1 for bit density, performance and power efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804147821/en/ Leveraging the companies’ revolutionary CMOS directly Bonded to Array (CBA) technology2 which fabricates CMOS logic and the memory array on separate wafers before bonding them together with high-precision wafer-to-wafer alignment, the new generation improves read and write bandwidth c
Altasciences Completes Expansion of Research and Development Laboratory in Harleysville, Pennsylvania4.8.2026 14:00:00 CEST | Press release
Altasciences is excited to share it has expanded the R&D laboratory at its drug product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804164599/en/ From left to right: Nasir Egal (General Manager, CDMO Services); Marie-Hélène Raigneau (Chief Executive Officer); Anuji Abraham (Senior Director, Pharmaceutical Development, CDMO Services); Robert Sabelli (Co-Chief Operating Officer); Cathy Konidas (Chief Administrative Officer) The expansion brings together formulation development and analytical testing within a single laboratory. This integrated setup is designed to accelerate decision-making, streamline workflows, and strengthen collaboration across scientific disciplines. “With this expansion, we are strengthening our focus on early-stage integration, bringing our CDMO capabilities t
Vasion® is Imprivata®-Ready Certified to Bring Trusted Identity Across Healthcare Print Infrastructure4.8.2026 14:00:00 CEST | Press release
New integration brings Imprivata Enterprise Access Management directly into the Vasion Platform: closing the identity gap at the print layer, enabling clinicians and healthcare users to securely release jobs at any printer with a single badge tap. Vasion, a leader in intelligent print automation, today announced a strategic integration with Imprivata, a leading digital identity and access management company for life- and mission-critical industries, starting with healthcare. The Vasion platform, with PrinterLogic®, PrinterLogic Output, and Vasion Automate, offers shared Imprivata customers a unified identity layer, spanning endpoints and printers, for secure, enterprise-wide visibility into every print job. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804404337/en/ The integration is designed to maximize existing Imprivata deployments. No rip-and-replace is required. The Vasion platform works with the Imprivata infrastr
Thredd and Pliant Expand Partnership to Launch U.S. Commercial Credit Program, Accelerate Embedded Finance for Businesses4.8.2026 14:00:00 CEST | Press release
Partnership enables cross-border expansion with a scalable, API-driven commercial credit and reconciliation platform built for speed to market Thredd, the AI-first issuer processing platform, today announced the expansion of its partnership with Pliant, bringing the company’s commercial credit and embedded finance platform capabilities to the U.S. market for the first time. Pliant provides European businesses with physical and virtual credit cards that have built-in reconciliation, spend controls, and deep integrations into modern finance stacks. Through its expanded partnership with Thredd, Pliant has successfully mirrored its established European proposition in the U.S., enabling American businesses to issue commercial credit cards that maintain real-time visibility into spend and cash-flow management. The program is live in the U.S. on the Visa network, with bank sponsorship provided by Coastal. The launch follows a successful soft rollout in late 2025, allowing Pliant to begin onbo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom